Web Exclusives

Web Exclusives | May 24, 2022
Recent survey results of physicians who treat patients with non–small-cell lung cancer reveal high biomarker testing rates, but treatment decisions frequently depend on test result turnaround time.
Web Exclusives | May 24, 2022
Newly diagnosed patients who adhered to tumor board recommendations for treatment have a longer overall survival time than patients who only partially adhered or did not adhere to recommendations.
Web Exclusives | May 24, 2022
Patients with KRAS G12C non–small-cell lung cancer appear to have improved progression-free survival before immunotherapy than patients with non-KRAS G12C lung cancer, but there was no improvement in overall survival between the 2 groups.
Web Exclusives | May 24, 2022
More severe interstitial lung disease with more severe radiological features was found on second occurrence in patients with lung cancer who were rechallenged with ICI treatment.
Web Exclusives | April 27, 2022
Liquid biopsy improves turnaround time for molecular genotyping, but further improvement in next-generation sequencing is recommended.
Web Exclusives | April 27, 2022
A recent study identified several risk factors associated with the development of nephrotoxicity when using pemetrexed in patients with non–small-cell lung cancer.
Web Exclusives | April 27, 2022
Researchers identified an association between nutritional status, treatment protocols, and survival in patients with advanced non–small-cell lung cancer.
Web Exclusives | April 27, 2022
Recently released study findings on PD-1/PD-L1 immunotherapy in young and elderly patients with metastatic NSCLC found the treatment is safe and effective in both patient cohorts.
Web Exclusives | March 28, 2022
Next-generation sequencing for targetable mutations in lung cancer is as accurate as single-gene testing with minimal increase in testing cost.
Web Exclusives | March 28, 2022
Released study results indicate that an interval of ≤50 days from diagnosis to treatment significantly improves outcomes in patients with early-stage lung cancer.
Web Exclusives | March 28, 2022
A recent review article examined the limited benefit associated with immune checkpoint inhibitor use in patients with non–small-cell lung cancer with poor performance status.
Web Exclusives | March 28, 2022
Smoking cessation ≥3 weeks prior to lung cancer surgery significantly decreases postoperative complications.
Web Exclusives | February 22, 2022
The chemistry behind selective KRAS G12C therapies and potential future research avenues were discussed in a recently released journal article.
Web Exclusives | February 22, 2022
In a recent study, researchers identified several factors associated with the development of pneumonitis with therapies targeting non–small-cell lung cancer.
Web Exclusives | February 22, 2022
Considerations in first-line and second-line therapy selection in non–small-cell lung cancer without genetic alterations were presented in a recent review article.
Web Exclusives | February 22, 2022
Although generally mild adverse events are associated with the use of immune checkpoint inhibitors for non–small-cell lung cancer, occasionally serious complications may result.
Web Exclusives | January 25, 2022
A recent review of the various approaches to developing new therapeutic drugs to treat KRAS-harboring tumors also discusses emerging drugs.
Web Exclusives | January 25, 2022
Molecular testing of early-stage non–small-cell lung cancer is recommended after clinical trial results demonstrate osimertinib is effective for patients with EGFR-harboring tumors.
Web Exclusives | January 25, 2022
A retrospective cohort study demonstrates patients with inoperable non–small-cell lung cancer receiving aspirin have improved overall survival compared with patients not receiving aspirin.
Web Exclusives | January 25, 2022
A recent review of case reports of patients with non–small-cell lung cancer receiving immune checkpoint therapy finds neurologic adverse events are a rare but concerning side effect.
Web Exclusives | December 22, 2021
Recently released results using liquid biopsy shows KRAS G12C mutation in patients with NSCLC can be lost or acquired at progressive disease.
Web Exclusives | December 22, 2021
Social listening can offer investigators valuable information about unmet patient needs and concerns regarding their cancer treatment and to direct future research.
Web Exclusives | December 22, 2021
Researchers found a large underrepresentation gap among minority populations across major cancer types in clinical trials.
Web Exclusives | December 22, 2021
Improved understanding of self-care behaviors in patients with cancer who take oral anticancer medications can help healthcare professionals support patient medication adherence.
Web Exclusives | December 20, 2021
Providing quality care requires understanding the disease factors, clinical presentation, and management strategies for immunotherapy-induced cytokine release syndrome with acute lymphoblastic leukemia treatment.
Web Exclusives | December 20, 2021
An overview of the clinical presentation, management approaches, and clinical practice guidelines for immunotherapy-related neurotoxicity in acute lymphoblastic leukemia treatment is presented.
Web Exclusives | December 20, 2021
Clinicians should recognize the prognostic importance of minimal residual disease testing and its implications for treatment pathways in acute lymphoblastic leukemia.
Web Exclusives | December 20, 2021
Navigating the complexities of acute lymphoblastic leukemia treatment requires a multidisciplinary team approach to the management of multiple care needs in inpatient and outpatient settings.
Web Exclusives | December 20, 2021
Successful transitions of care from the hospital to the home setting for patients with acute lymphoblastic leukemia requires a team of hospital and outpatient clinicians to provide coordinated care and support.
Web Exclusives | December 14, 2021
In a follow-up analysis, second-line nivolumab in advanced/recurrent esophageal squamous-cell carcinoma showed significant median overall survival benefit compared with chemotherapy.
Page 1 of 7
Results 1 - 30 of 198

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country
  • Please enter your mailing address.

    Address
     
    Address Line 2
    City
     
    State
    Zip Code